High-risk morphological features are less prevalent among small (<5mm) papillary thyroid microcarcinomas compared to larger (≥5mm) tumors: a study of 206 cases

Emőke - Andrea Szász¹, Adela Nechifor-Boilă¹,², Ancuţa Zahan¹, Angela Borda¹,³

1. Department of Histology, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Romania
2. Department of Pathology, Targu Mures County Hospital, Targu Mures, Romania
3. Department of Pathology, Targu Mures Emergency County Hospital, Targu Mures, Romania

Introduction: Papillary thyroid microcarcinoma (PTMC) is defined as a PTC measuring 1 cm or less, incidentally discovered. The aim of this study was to determine whether small (<5mm) tumors by contrast with large (≥5mm) ones are less frequently associated with high-risk morphological features, predictive of tumor aggressiveness.

Materials and methods: All consecutive PTMC cases registered at the Department of Pathology, Târgu-Mureş Emergency County Hospital between 2003-2014 were reviewed. The following have been assessed: tumor size, subcapsular versus nonsubcapsular location, extrathyroidal extension/invasion into the perithyroidal adipose tissue, multifocality, resection margins, lymph node involvement, histological variant, tumor border, stromal reaction (fibrosis/desmoplasia/sclerosis), presence of plump pink cells, nuclear features of the tumor cells, intratumoral lymphocytic infiltrate, multinucleated giant cells, psammoma bodies and stromal calcification. The cases were split in two categories: small (< 5mm) and large (≥ 5mm) PTMCs and the pathological features were evaluated in comparison.

Results: Our study included 206 cases, 91 large and 115 small PTMCs, respectively. Large PTMCs were significantly associated with the presence of plump pink cells (p=0.002), well developed PTC nuclear features (p=0.003), stromal reaction (fibrosis/desmoplasia/sclerosis) (p=0.001), infiltrative tumor border (p=0.011), subcapsular location (p=0.001), positive resection margins (p=0.022), stromal calcifications (p=0.001) and intratumoral multinucleated giant cells (p=0.001). Small PTMCs were generally well circumscribed and nonsubcapsular.

Conclusions: Our results have shown that small (<5mm) PTMCs are less frequently associated with high-risk morphological features, predictive of tumor aggressiveness compared with large (≥5mm) tumors and could thus be considered as low-risk cancers.

Keywords: papillary, microcarcinoma, thyroid, tumor size, plump cells

Received 23 March 2021 / Accepted 21 April 2021

Introduction

Worldwide, the incidence of thyroid cancer has significantly increased over the past decades [1, 2]. This is mainly related to the rapid increase in the incidence of small, incidentally discovered, subcentimetric papillary thyroid carcinomas (PTC), namely microcarcinomas (PTMC) [3, 4]. This increase might be explained by the widespread use of imaging techniques and fine needle aspiration (FNA) biopsy of small thyroid nodules, allowing the identification of a large number of clinically silent PTMCs [5]. Moreover, many PTMCs have lately been detected following advances in the sampling technique and a more watchful and careful examination of the thyroid specimens resected for benign diseases [6]. All this together, resulted in an increased detection of PTMCs, considered as a global phenomenon called epidemic of overdiagnosis [1, 7, 8].

Despite this, many current guidelines and recommendations regarding the optimal treatment strategy for PTMC remain controversial [9]. The management of PTMC ranges from observation alone to total thyroidectomy +/- central lymph node dissection [10]. This reflects our inability to accurately predict the aggressiveness of PTMCs before surgery [9, 11]. The prognosis of PTMC is excellent in the great majority of cases [3, 12], although some PTMCs might behave more aggressively, but no definite biological or clinical parameters currently exist to distinguish indolent PTMCs from potentially aggressive PTMCs [13].

PTMCs that have poorer prognosis are usually multifocal, incompletely resected, have extrathyroidal extension or lymph node involvement [14, 15]. Some microscopic morphological features have also been shown to predict potential aggressiveness in PTC cases. These include: the histological variant (eg. conventional and tall cell versus follicular variant), infiltrative tumor borders, well developed nuclear features of PTC, stromal reaction (including fibrosis, desmoplasia and/or sclerosis), focal polygonal eosinophilic (plump pink) cells, presence of psammoma bodies [16, 17]. The problem is that all these features are available only after surgery.

Tumor size, by contrast, is the most available preoperative parameter, as it can easily be assessed by ultrasonography.

In this study, we analyzed and assessed the morphological features of PTMCs in a large series of cases, including <5mm and ≥5mm tumors. Our aim was to determine whether small (<5mm) tumors by contrast with large...
(≥5mm) ones are less frequently associated with high-risk morphological features, predictive of tumor aggressiveness and could thus be regarded as low-risk cancers.

Material and Methods
Selection of the cases
After obtaining the approval of the Ethics Committee of “George Emil Palade” University of Medicine, Pharmacy, Sciences and Technology of Târgu-Mureș, we conducted a retrospective study on a series of PTMCs. The cases included in the study were registered in the database of the Pathology Department, Târgu-Mureș Emergency County Hospital from January 2003 to December 2014. The cases were included in the study if (1) the diagnosis was PTMC and (2) the corresponding hematoxylin/eosin (HE)-stained slides were available for review.

Pathological data
For all the cases included in the study, the corresponding slides (HE-stained) were reviewed by three pathologists interested in endocrine pathology (EAS, ANB and AB). All controversial features were analyzed and discussed together at the triple-headed microscope. The following morphological features have been assessed: the size of the tumor, the tumor location (subcapsular versus nonsubcapsular), the extrathyroidal extension/invasion into the perithyroidal adipose tissue, the multifocality, the resection margins, the lymph node involvement, the histologic variant (conventional PTC versus variants of PTC: follicular, tall cell, Warthin-like, oncocytic), the tumor margins (well circumscribed (not encapsulated/encapsulated) versus infiltrative), the stromal reaction (fibrosis/desmoplasia/sclerosis versus none of these changes), the presence of plump pink cells, intratumoral lymphocytic infiltrate, psammoma bodies, stromal calcification and the nuclear features.

The diagnosis of PTMC, as well as the histological variant of the tumor (conventional PTC versus variants of PTC: follicular, tall cell, oncocytic, Warthin-like) were all set in accordance to the 2017 WHO (World Health Organization) Classification of Tumors of Endocrine Organs [18].

Subcapsular PTMCs were defined as tumors located under the thyroid capsule, with 0-0.1mm distance between the edge of the tumor and the thyroid capsule; nonsubcapsular PTMCs were defined by a >0.1mm distance between the edge of the tumor and the thyroid capsule (Fig. 1 A, B). Extrathyroidal extension (ETE) was defined as limited tumor extension either into adipose perithyroidal soft tissues (Fig. 1 C) or into the strap muscles (sternohyoid, sternothyroid or omohyoid muscles) according to the 2009 AJCC [19] or only strap muscles invasion, according to the 2017 AJCC [20]. As it is a retrospective study, all cases were assessed according to 2009 AJCC classification system and were reassessed based on current 2017 AJCC classification system. Multifocality was defined as the presence of two or more isolated/non-contiguous tumor foci in one or both thyroid lobes. Lymph node involvement (pN1) was defined as metastasis into at least one regional lymph node (Fig. 1 D).

Tumor associated stromal reaction was also documented. Fibrosis was defined as the presence of fibroblasts in a collagenous (non-mixoid) stroma (Fig. 2 A), desmoplasia as the presence of proliferating fibroblasts in a myxoid stroma, and sclerosis as the presence of paucicellular, eosinophilic, dense bundles of collagen (Fig. 2 B) [16]. The degree of tumoral fibrosis was also evaluated and scored, as follows: fibrosis 1+ (mild fibrosis with the presence of few inconspicuous, delicate fibrous areas within or at the periphery of the tumor nodule) and fibrosis 2+ (moderate/extensive fibrosis that was clearly recognizable, with multiple fibrotic bands within and at the periphery of the tumor nodule) [21]. The presence of psammoma bodies and stromal calcification was also noted (Fig. 2 C, D).

Multinucleated giant cells, as well as plump pink cells (large polygonal tumor cells with nuclear features of PTC and moderate to abundant homogenous, eosinophilic cytoplasm, that were not “tall enough” to be like the cells in the tall-cell PTC variant) were carefully evaluated if present [16, 22] (Fig. 3 A, B).

Further on, the tumor cell nuclei were assessed for seven nuclear features: nuclear enlargement, overlapping, grooves, irregular nuclear membrane, chromatin clearing, pseudoinclusions (Fig. 3 C) and “sickle” nuclei (smaller, eccentrically located nuclei, with a particular sickle shape) [23] (Fig. 3 D). Well-developed PTC nuclear features were considered if ≥5 nuclear features were present and poorly developed if fewer (≤4) nuclear features were present.

The tumor size was measured in millimeters, under the microscope (Olympus BX46, Olympus Life Science, Waltham, Massachusetts, USA) at low magnification (40×). Based on this parameter, the cases were divided in two categories: small (< 5mm) and large (≥ 5mm) PTMCs. All the pathological features were assessed in comparison between these two groups.

Statistical analysis
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS), version 20, Chicago, IL, USA). Data were labeled as nominal or quantitative variables. Nominal variables were characterized by means of frequencies. Quantitative variables were tested for normality distribution using Kolmogorov-Smirnov test and were described by mean ± standard deviation or median and percentiles (25; 75%), whenever appropriate. The frequencies of nominal variables were compared with a chi-square test. Differences in the mean or median between groups were analyzed using the t test. The level of statistical significance was set at p< 0.05.

Results
A total of 221 patients with PTMC were registered at the Department of Pathology, Târgu-Mureș Emergency Coun-
Fig. 1. Papillary thyroid microcarcinomas, morphological features (hematoxylin/eosin). Nonsubcapsular, conventional papillary thyroid microcarcinoma (A, x 2.5); Subcapsular conventional papillary thyroid microcarcinoma (B, x 2.5); Subcapsular papillary thyroid microcarcinoma that extends into the perithyroidal soft tissue (C, x 5); Lymph node involvement of papillary thyroid microcarcinoma (D, x 5).

Fig. 2. Stromal reaction in papillary thyroid microcarcinomas (hematoxylin/eosin). A papillary thyroid microcarcinoma case showing fibrosis with multiple fibrotic bands within the tumor (A, x 10); A papillary thyroid microcarcinoma case showing sclerosis with the presence of paucicellular, eosinophilic, dense bundles of collagen and psammoma bodies (B, x 10); Psammoma bodies in a papillary thyroid microcarcinoma case (C, x 10); Stromal calcification in a papillary thyroid microcarcinoma case (D, x 10).
ty Hospital during the study period. Out of these, fifteen cases were excluded from our analysis because: (1) the tumors did not meet all the diagnostic criteria for PTMC (n=9 cases) or (2) the histological slides were not available for evaluation (n=6 cases). The remaining 206 PTMC cases were further included in the study; 91 were large (≥5mm) and 115 were small (<5 mm) PTMCs.

Table I shows the demographic and morphological characteristics of the study cases. No differences in terms of sex and age between small and large PTMCs were observed. The majority of cases occurred in women, both in small (n=104, 89.6%) and large (n=91, 93.4%) PTMCs (p=0.550). The mean age at diagnosis was 53.1± 10.16 and 51.09±10.48 years-old for small and large PTMCs, respectively (p=0.130).

Approximately half of the cases were consistent with a diagnosis of conventional PTMCs in small PTMCs (51.3%). Other PTC variants (tall cell, oncocytic, Warthin-like) accounted for only few cases (n=19, 9.2% in total) and, although not reaching statistically significant values (p=0.161), appeared to be rather more numerous among large PTMCs.

Large PTMCs were found to be significantly associated with subcapsular location (p=0.0001) and infiltrative tumor border (p=0.011), compared to small PTMCs. Unlike large PTMCs, small PTMCs were nonsubcapsular in the great majority of cases (n=97/115, 84.3%). More than half had either well circumscribed tumor border (36.5%) or were encapsulated tumors (21.7%). Seven cases of large and only one case of small PTMC had positive resection margins (p=0.022) and were all located in the subcapsular area.

None of the 206 PTMC cases showed extension into the strap muscles, defined as extrathyroidal extension by the 8th/2017 AJCC. If the 7th/2009 AJCC definition of extrathyroidal extension was applied, 18 cases were extrathyroidal, revealing tumor invasion into the perithyroidal adipose tissue; the differences were statistically significant when comparing small to large PTMCs (p=0.002). Multifocality was documented in 45.2% small PTMCs, compared to 33% large PTMCs (p=0.086). Lymph node dissection was performed in only 11 cases (5.3%). Of these, three cases displayed lymph node involvement and they were all subcapsular, large PTMCs, with infiltrative tumor borders.

Stromal reaction (fibrosis, desmoplasia or sclerosis) was significantly more prevalent among large versus small PTMCs (p=0.0001). Also, when scoring fibrosis, both fibrosis 1+ (45.1% versus 28.7%) and 2+ (26.4% versus 20%) were significantly more prevalent among large versus small PTMCs. Intratumoral multinucleated giant cells were documented in 31 (15%) PTMCs, and they were more frequently present among large PTMCs (27.5% versus 5.2%, p<0.001). Ten cases of large PTMCs showed stromal calci-
Psammoma bodies were slightly more prevalent among large PTMCs (15.4% versus 8.7%, p=0.189), whereas the presence of lymphocytes was more prevalent among small PTMCs (24.6% versus 19.8%, p=0.501).

Plump pink tumor cells were documented in 48 (23.3%) PTMCs, mainly among large PTMCs compared to small PTMCs (34.1% versus 14.8%, p=0.002). Large PTMCs were significantly associated with nuclear features such as irregular nuclear membranes (p<0.001) and pseudoinclusions (p<0.001). "Sickle"-shaped nuclei were identified with almost equal distribution among large PTMCs (n=23, 25.3%) and small PTMCs (n=21, 18.3%) cases (p=0.065). Well-developed nuclear features were present almost in all large PTMCs (90.1%, p=0.003).

**Discussion**

Papillary thyroid microcarcinoma becomes a more and more frequent diagnosis in many countries around the world [14, 3]. It is accepted that these small papillary thyroid cancers are common and rarely behave as aggressive cancers, with extrathyroidal extension and lymph node and distant metastasis [24]. Therefore, the biological characteristics of PTMC have gradually attracted more attention from researchers [25]. The main questions for the clinician remain (1) how to distinguish between harmless and harmful PTMCs and (2) which PTMCs can adequately and safely be managed by active surveillance as an alternative to immediate surgery [26]. The current guidelines also recognized active surveillance as the best alternative for the patients with low-risk PTMCs [10, 27].

### Table I. Demographic and morphological differences between large (≥5mm) versus small (<5mm) papillary thyroid microcarcinomas in our study.

| Demographic and morphological features | Tumor <5 mm | Tumor ≥5 mm | p     |
|---------------------------------------|-------------|-------------|-------|
| Age at diagnosis (mean±SD, years)     | 53.1±10.16  | 51.9±9.48   | 0.130 |
| Female sex                            | 104 (88.6%) | 83 (92.4%)  | 0.550 |
| Location                              | <0.001      |             |       |
| Subcapsular                           | 17 (14.8%)  | 59 (64.8%)  |       |
| Nonsubcapsular                        | 97 (84.3%)  | 33 (36.3%)  |       |
| Extrathyroidal extension               |             |             | 0.002 |
| 8th TNM                               | 0 (0.0%)    | 0 (0.0%)    |       |
| 7th TNM                               | 8 (6.9%)    | 10 (11.0%)  |       |
| Multilocularity                        | 52 (45.2%)  | 30 (33.0%)  | 0.086 |
| Positive resection margin              | 1 (0.9%)    | 7 (7.7%)    | 0.022 |
| Lymph node involvement *              | 0/0 (0.0%)  | 3/11        | 0.085 |
| Histological variant                  |             |             | 0.161 |
| Conventional                          | 59 (51.3%)  | 43 (47.2%)  |       |
| Follicular                            | 50 (43.5%)  | 35 (38.5%)  |       |
| Tall cell                             | 0 (0.0%)    | 1 (1.1%)    |       |
| Oncocytic                             | 4 (3.5%)    | 6 (6.6%)    |       |
| Warthin-like                          | 2 (1.7%)    | 6 (6.6%)    |       |
| Tumor border                          |             |             | 0.011 |
| Well-circumscribed, non-encapsulated  | 42 (36.5%)  | 23 (25.3%)  |       |
| Encapsulated                          | 25 (21.7%)  | 11 (12.1%)  |       |
| Infiltrative                          | 48 (41.7%)  | 57 (62.6%)  |       |
| PTC nuclear features                  |             |             |       |
| Nuclear enlargement                   | 115 (100.0%)| 91 (100.0%) |       |
| Overlapping                           | 113 (88.3%) | 87 (95.6%)  | 0.409 |
| Irregular nuclear membrane            | 85 (73.9%)  | 87 (95.6%)  | <0.001|
| Grooves                               | 112 (97.4%) | 91 (100.0)  | 0.257 |
| Chromatin clearing                    | 113 (88.3%) | 87 (95.6%)  | 0.409 |
| Pseudoinclusions                      | 37 (32.2%)  | 56 (61.5%)  | <0.001|
| Sickle shaped                         | 21 (18.3%)  | 23 (25.3%)  | 0.065 |
| Well-developed PTC nuclei             | 86 (74.8%)  | 82 (90.1%)  | 0.003 |
| Poorly developed PTC nuclei           | 29 (25.2%)  | 9 (9.9%)    |       |
| Tumor associated stromal reaction     | <0.001      |             |       |
| None                                  | 52 (45.2%)  | 28 (30.8%)  |       |
| Fibrosis                              | 46 (40.0%)  | 24 (26.4%)  |       |
| Desmoplasia                           | 10 (8.7%)   | 13 (14.3%)  |       |
| Sclerosis                             | 7 (6.1%)    | 28 (29.6%)  |       |
| Tumor fibrosis                        | <0.004      |             |       |
| None                                  | 59 (51.3%)  | 26 (28.6%)  |       |
| Fibrosis 1+(mild)                     | 33 (28.7%)  | 41 (45.1%)  |       |
| Fibrosis 2+(moderate/extensive)       | 23 (20.0%)  | 24 (26.4%)  |       |
| Plump, pink cells                     | 17 (14.8%)  | 31 (34.1%)  | 0.002 |
| Intratumoral lymphocytic infiltrate    | 26 (24.6%)  | 18 (19.8%)  | 0.501 |
| Intratumoral multinucleated giant cells | 6 (5.2%)  | 25 (27.5%)  | <0.001|
| Psammoma bodies                       | 10 (8.7%)   | 14 (15.4%)  | 0.189 |
| Stromal calcification                 |             |             | <0.001|
| None                                  | 0 (0.0%)    | 10 (11.0%)  |       |

PTMC: papillary thyroid microcarcinoma; PTC: papillary thyroid carcinoma; *Data regarding only cases with lymph node dissection (no. of cases with lymph node involvement/no. of cases with lymph node dissection). The level of statistical significance was set at p< 0.05 and the differences are shown in bold.
Tumor size is considered to be an essential prognostic factor in patients with PTMC [28]. A close relationship between larger tumor size and worse outcome, both in terms of recurrence and survival is documented in the literature, but with controversies regarding the optimal cut-off value for defining small and large PTMCs [9]. Lim et al indicated that this cut-off value could be 7 mm [29], Zhang et al. that it could be 6 mm [30] and Chang et al. suggested 5 mm as the cut-off value [31]. Lombardi et al. also demonstrated that tumor size >5 mm was significantly associated with invasion into the perithyroidal adipose tissue [32]. Other groups have found no relationship between PTMC size and the presence of high-risk features [33, 34].

Previous studies demonstrated that PTMC with a larger tumor size may behave more similar to PTC. Gong et al. suggested 8.5 mm as the adequate tumor size to distinguish PTMC from PTC [11]. Song et al demonstrated that tumor size larger than 6.5 mm represent a risk factors for cervical lymph node metastases [34].

The size of the tumor is widely used to predict the aggressiveness of PTMC because it is the easiest parameter to determine using ultrasound images. In this study, we analyzed and assessed the morphological features of PTMCs in a large series of cases, including <5mm and ≥5mm tumors. Our aim was to determine whether small (<5mm) tumors by contrast with large (≥5mm) ones are less frequently associated with high-risk morphological features, predictive of tumor aggressiveness and could thus be regarded as low-risk cancers.

Our results have highlighted important morphological differences between the two PTMC groups (≥5mm versus <5 mm). High-risk morphological features were significantly more prevalent among large PTMCs compared with small PTMCs. Large PTMCs were located mostly in the subcapsular area and had infiltrative borders. By contrast, small PTMCs were nonsubcapsular in the great majority of cases and had well circumscribed tumor border or were encapsulated. Recently Tallini et al. have demonstrated that tumor's location (subcapsular versus nonsubcapsular) and tumor size (<5mm versus ≥5 mm) represent valuable morphological tools in the proper selection of patients for active surveillance [35]. The subcapsular location of the tumor, immediately adjacent to the perithyroidal adipose tissue has been recognized as an adverse prognostic factor [24]. This is not unexpected, because subcapsular tumors have an easy access to the extrathyroidal soft tissues. In our study only eighteen PTMCs showed invasion into the perithyroidal adipose tissue, that was seen significantly more often among large, subcapsular PTMCs.

We have also shown that large PTMCs were more frequently associated with other high-risk morphological features, like stromal reactions (fibrosis/desmoplasia/sclerosis) (p<0.001), intratumoral multinucleated giant cells (p<0.001), calcifications (p<0.001) and polygonal plump pink cells (p=0.002). Small PTMCs revealed a completely different morphological profile. Unlike large PTMCs, small tumors were characterized by a scarcity of tumor-associated stromal reactions (p<0.001), plump pink cells (p=0.002), and multinucleated giant cells (p<0.001).

Only few studies in the literature have investigated the importance of multinucleated giant cells in PTCs. Probably these cells are a response to abnormal colloid productions in PTC [36]. Although multinucleated giant cells have been described most commonly in inflammatory conditions of the thyroid, some studies have demonstrated that the presence of multinucleated giant cells were associated with lymph node metastasis and advanced stage of PTC [37]. The results of our study demonstrated their presence mainly in larger tumors and this should prompt a careful evaluation of large PTMCs.

The plump cell morphology has yield importance as a morphological feature predictive for poor prognosis in PTC back in 2013 with the study of Virk RK et al. [16]. In line with this, our results revealed a high prevalence of plump pink cells among large PTMCs and a scarcity of these cells among small PTMCs.

Large PTMCs revealed well developed nuclear features of PTC in most of the cases, whereas subtle nuclear features of PTC were more frequently present among small PTMCs.

In the present study, lymph node dissection was performed in 11 cases. Of these, three cases showed lymph node involvement, all large PTMCs. Several authors have demonstrated that PTMCs with >5 mm in diameter are significantly more frequently associated with central lymph node metastasis compared to <5 mm PTMCs [38]. Clinical ultrasound studies have also shown that ≥5 mm, subcapsular tumors are more likely to be associated with lymph node metastases, compared to smaller tumors [39, 40]. In our study, no small, <5mm PTMC case was associated with lymph node metastasis, but no definite conclusion regarding tumor size and lymph node involvement can be drown due to the limited number of PTMCs with lymph node dissection.

The current study has some limitations. It is a retrospective analysis from a single institution and results may not be generalizable to all populations. Further on, an important morphological parameter, lymph node involvement could not be evaluated with optimal accuracy due to the limited number of PTMC cases in which lymph node dissection was performed. This is mainly related to the diagnosis of cancer being established after surgery for the majority of cases in our study.

**Conclusions**

We have shown that small (<5mm) PTMCs are less frequently associated with high-risk morphological features, predictive of tumor aggressiveness compared with large (≥5mm) tumors. It is uncertain and still a matter of debate whether these high-risk morphological features are less frequently present in small compared to large PTMCs because of their different biological phenotype or because...
they did not have time to develop. However, based on our results, small, <5mm PTMCs could be considered as low-risk cancers and, thus possible candidates for active surveillance instead of immediate surgery. Further broader studies, with long-term follow-up data are however needed to confirm these results.

**Authors’ contribution**

EAS - Data collection, conceptualization, histological examination of the cases, writing and editing
ANB - Histological examination of the cases, writing and editing
EAS - Data collection, conceptualization, histological examination, with long-term follow-up data are however needed to predict BFRAV600E -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience. Cancer Cytopathol. 2014;122:883-889.

**Conflict of interest**

None to declare.

**References**

1. Ahn HS, Kim HJ, Welsh HG. Korea’s thyroid-cancer “epidemic”: screening and overdiagnosis. N Engl J Med. 2014;371:1765-1767.
2. Cramer JD, Fu PF, Harth KC et al. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology, and End Results national cancer data registry. Surgery. 2010;148:1147-1152.
3. Davies LW, Welsh HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317-322.
4. Puszastzer MP, Tamila M, Payne RJ. Active surveillance for low-risk small papillary thyroid cancer in North American countries: past, present and future (bridging the gap between North American and Asian practices). Gland Surg. 2020;9:1685-1697.
5. Van L, Blanco J, Reddy V et al. Clinicopathological features of papillary thyroid microcarcinoma with a diameter less than or equal to 5mm. Am J Otolaryngol. 2019;40:560-563.
6. Zahan AE, Netchir-Bolòc AC, Paşcaru I, et al. Papillary Thyroid Microcarcinomas: a 25 Years Retrospective, Institutional Study of 255 Cases. Acta Marisiensis - Seria Medica. 2016;62:41-46.
7. Welch HG. Cancer Screening, Overdiagnosis, and Regulatory Capture. JAMA Intern Med. 2017;177:915-916.
8. Vaccumrella S, Franceschi S, Bray F et al., Worldwide Thyroid-Cancer Epicemic? The Increasing Impact of Overdiagnosis. N Engl J Med. 2016;375:614-617.
9. Wang M, Wu WD, Chen GM, et al., Could Tumor Size Be A Predictor for Papillary Thyroid Microcarcinoma: a Retrospective Cohort Study. Asian Pac J Cancer Prev. 2015;16:8625-8629.
10. Haugen BR, Alexander EK, Bible KC et al., 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1-153.
11. Gong Y, Li G, Lei J et al. A favorable tumor size to define papillary thyroid microcarcinoma: an analysis of 1176 consecutive cases. Cancer Manag Res. 2018;10:899-906.
12. Lim H, Devesa SS, Sosa JA, et al. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2015. JAMA. 2017;317:1336-1348.
13. Kalsziewski K, Diakowksa D, Wójcik B et al. Which papillary thyroid microcarcinoma should be treated as “true cancer” and which as “precancer”? World J Surg Oncol. 2019;17:91.
14. Liu C, Wang S, Zeng W et al. Total tumor diameter is superior to unifocal diameter as a predictor of papillary thyroid microcarcinoma prognosis. Sci Rep. 2017;7:1846.
15. Xu D, Lv X, Wang S et al. Risk factors for predicting central lymph node metastasis in papillary thyroid microcarcinoma. Int J Clin Exp Pathol. 2014;7:6199-205.
16. Vrk RK, Van Dyke AL, Finkelstein A et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Med Pathol. 2015;22:62-70.
17. Jiang J, Lu H. Immediate Surgery Might Be a Better Option for Subcapsular Thyroid Microcarcinomas. Int J Endocrinol. 2019;2019:3619864.
18. Rosas J, Alberos Saavedra J, Asiel S et al. Papillary thyroid carcinoma in Lloyd RV, Osamura RR, Klöppel G et al. (eds): WHO classification of tumours of endocrine organs. 4th edition. International Agency for Research on Cancer (IARC), Lyon, France, 2017, 81-91.
19. Sobin LH, Gospodarowicz MK, Wittekind C. UICC/TNM Classification of Malignant Tumours. 7th edition. John Wiley & Sons. Oxford, UK, 2009, 56-58.
20. Brierley JD, Gospodarowicz MK, Wittekind C. UICC/TNM Classification of Malignant Tumours. 8th edition. John Wiley & Sons. Oxford, UK, 2017, 51-55.
21. Niermeier LA, Aciaru K, Song OH et al. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer. 2012;118:2069-2077.
22. Finkelstein A, Levy GH, Hui P et al. Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology. 2012;60:1052-1059.
23. Rossi ED, Bizzarro T, Martiní M et al., Morphological parameters able to predict BFRAV600E -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience. Cancer Cytopathol. 2014;122:883-889.
24. Wada N, Duh QY, Sugino K et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399-407.
25. Shi C, Guo Y, Li Y et al. Clinicopathological Features and Diagnosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors. PLoS One. 2016;11:e0167414.
26. Qian K, Guo K, Zheng X et al. Contrastive study of two screening criteria for active surveillance in patients with low-risk papillary thyroid microcarcinoma: a retrospective analysis of 1001 patients. Oncotarget. 2017;8:65836-65846.
27. Miyazchi A. Clinical Trials of Active Surveillance of Papillary Thyroid carcinoma of the Thyroid. World J Surg. 2016;40:516-522.
28. Zheng X, Peng C, Gao M et al. Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients. Cancer Biol Med. 2019;16:121-130.
29. Lim YC, Choi EC, Yoon YH et al. Central lymph node metastases in unilateral papillary thyroid microcarcinoma. Br J Surg. 2008;95:253-257.
30. Zhang L, Wei WJ, Li QH et al. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab. 2017;92:1250-1257.
31. Chang YW, Kim HS, Kim HY et al. Should central lymph node dissection be considered for all papillary thyroid microcarcinoma? Asian J Surg. 2016;39:197-201.
32. Lombardi CP, Bellantone R, De Crea C et al. Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World J Surg. 2010;34:1214-1223.
33. Petizzo MR, Boschin IM, Tonio A et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun. 2004;25:547-552.
34. Song J, Yan T, Qiu W et al. Clinical Analysis of Risk Factors for Cervical Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Retrospective Study of 3686 Patients. Cancer Manag Res. 2020;12:2523-2530.
35. Talini G, De Leo A, Repaci A et al. Does the Site of Origin of the Microcarcinoma with Respect to the Thyroid Surface Matter? A Multicenter Pathologic and Clinical Study for Risk Stratification. Cancers (Basel). 2020;12:246.
36. Ryder M, Ghossein RA, Ricarte-Filho CM et al. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15:1069-1074.
37. Qing W, Fang W, Ye L et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcioma. Thyroid. 2012;22:905-910.
38. Tao Y, Wang C, Li L et al. Clinicopathological features for predicting central and lateral lymph node metastasis in papillary thyroid microcarcinoma: Analysis of 66 cases that underwent central and lateral lymph node dissection. Mol Clin Oncol. 2017;9:49-55.
39. Brito JP, Ito Y, Miyazchi A et al. A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. Thyroid. 2016;26:144-149.
40. Luo Y, Zhao Y, Chen K et al. Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma. J Endocrinol Invest. 2019;42:227-236.